• Aucun résultat trouvé

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

N/A
N/A
Protected

Academic year: 2021

Partager "SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: inserm-03261177

https://www.hal.inserm.fr/inserm-03261177

Submitted on 15 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SGLT-2 inhibitors and GLP-1 receptor agonists for

nephroprotection and cardioprotection in patients with

diabetes mellitus and chronic kidney disease. A

consensus statement by the EURECA-m and the

DIABESITY working groups of the ERA-EDTA

P. Sarafidis, C. J. Ferro, E. Morales, A. Ortiz, J. Malyszko, R. Hojs, K.

Khazim, R. Ekart, J. Valdivielso, D. Fouque, et al.

To cite this version:

P. Sarafidis, C. J. Ferro, E. Morales, A. Ortiz, J. Malyszko, et al.. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, Oxford University Press (OUP), 2020, 35 (10), pp.1825. �10.1093/ndt/gfz137�. �inserm-03261177�

(2)

Pantelis Sarafidis, Charles J. Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko,

Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque, Ge´rard M. London, Ziad Massy, Petro Ruggenenti, Esteban Porrini, Andrzej Wiecek, Carmine Zoccali,

Francesca Mallamaci and Mads Hornum

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA, Nephrology Dialysis Transplantation 2019; gfy407. doi: 10.1093/ndt/gfy407

In the original article, the words ‘micro- or microalbuminuria’ should have read ‘micro- or macroalbuminuria’ in the top boxes of Figures 4 and 5.

doi: 10.1093/ndt/gfz137 Advance Access publication 9 August 2019

Errata 1825

Références

Documents relatifs

Fourth, it would be helpful, in particular for medical stu- dents and residents, if the authors could rank the relevance of the different topics within a chapter (e.g.,

Lectura e interpretación de planos, bosquejos de obra, cálculo de costos y elaboración de presupuestos, orden de trabajo, uso de equipo de protección personal, materiales

The strength of our study is the standardized evaluation of diabetic patients including a questionnaire of possible osteoporosis risk factors and BMD measurements, which applied

Other covariates that were simultaneously included in these six multivariable linear regression models along with e-GFR CKD-EPI levels and abnormal albuminuria were as follows:

Although the exact serum (S K ) or plasma potassium (P K ) concentration associated with increased mortality remains controversial, growing evidence suggests that in patients with

The functional interaction of these receptors is also supported by the BRET signals observed when monitoring β-arrestin2 recruitment proximal to CCR2 in the presence of AT 1

Late-Stage Diversification of Imidazole-Based Pharmaceuticals Through Pd- Catalyzed Regioselective C–H Bond Arylations.. Amal Benzai, ‡, † Xinzhe Shi, ‡ Fazia Derridj, †

In its disposition activities, the BRA has managed its properties as a portfolio to maximize public benefits and has utilized the strength of the private real estate